Association between IL-6 and related risk factors of metabolic syndrome and cardiovascular disease in young rats

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 8, 2015, Pages 13491-13499

  Bao, Pengli ^a   Liu, Geli ^a   Wei, Ying ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Animal model; Cardiovascular disease; IL 6; Metabolic syndrome; Obesity

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ANIMAL MODEL; ANTHROPOMETRY; ARTICLE; BLOOD BIOCHEMISTRY; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIASTOLIC BLOOD PRESSURE; ENZYME LINKED IMMUNOSORBENT ASSAY; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LIPID BLOOD LEVEL; LIVER SIZE; METABOLIC SYNDROME X; NONHUMAN; OBESITY; RAT; RISK FACTOR; SYSTOLIC BLOOD PRESSURE;

EID: 84943608933     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Kaur J. A comprehensive review on metabolic syndrome. Cardiol Res Pract 2014; 2014: 943162.
2. Atlas D. International Diabetes Federation. Hallado en: http://www.idf.org/diabetesatlas/5e/es/prologo2000.
3. Xavier H and Monte O. Atherosclerosis prevention in metabolic syndrome patients: from physiopathology to the farmacoeconomics of statins treatment. Rev Bras Med 2005; 62: 197-204.
4. Scott R, Donoghoe M, Watts GF, O’Brien R, Pardy C, Taskinen MR, Davis T, Colman PG, Manning P, Fulcher G, Keech AC; FIELD Study Investigators. Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the FIELD randomised trial. Cardiovasc Diabetol 2011; 10: 102.
5. Sattar N, McConnachie A, Shaper AG, Blauw GJ, Buckley BM, de Craen AJ, Ford I, Forouhi NG, Freeman DJ and Jukema JW. Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet 2008; 371: 1927-1935.
6. Singh AK and Kari JA. Metabolic syndrome and chronic kidney disease. Curr Opin Nephrol Hypertens 2013; 22: 198-203.
7. Sampey BP, Vanhoose AM, Winfield HM, Freemerman AJ, Muehlbauer MJ, Fueger PT, Newgard CB and Makowski L. Cafeteria Diet Is a Robust Model of Human Metabolic Synd-rome With Liver and Adipose Inflammation: Comparison to High-Fat Diet. Obesity 2011; 19: 1109-1117.
8. Baldwin W, McRae S, Marek G, Wymer D, Pannu V, Baylis C, Johnson RJ and Sautin YY. Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome. Diabetes 2011; 60: 1258-1269.
9. Gremese E and Ferraccioli G. The metabolic syndrome: the crossroads between rheumatoid arthritis and cardiovascular risk. Autoimmun Rev 2011; 10: 582-589.
10. Testa R, Olivieri F, Bonfigli A, Sirolla C, Boemi M, Marchegiani F, Marra M, Cenerelli S, Antonicelli R and Dolci A. Interleukin-6-174 G>C polymorphism affects the association between IL-6 plasma levels and insulin resistance in type 2 diabetic patients. Diabetes Res Clin Prac 2006; 71: 299-305.
11. Pickup J, Mattock M, Chusney G and Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997; 40: 1286-1292.
12. Eckel RH, Grundy SM and Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415-1428.
13. Aker S, Bantis C, Reis P, Kuhr N, Schwandt C, Grabensee B, Heering P and Ivens K. Influence of interleukin-6 G-174C gene polymorphism on coronary artery disease, cardiovascular complications and mortality in dialysis patients. Nephrol Dial Transplant 2009; 24: 2847-2851.
14. Hollman G and Kristenson M. The prevalence of the metabolic syndrome and its risk factors in a middle-aged Swedish population-Mainly a function of overweight? Eur J Cardiovasc Nurs 2008; 7: 21-26.
15. Goyenechea E, Parra D and Martínez J. Impact of interleukin 6 -174G>C polymorphism on obesity-related metabolic disorders in people with excess in body weight. Metab Clin Exp 2007; 56: 1643-1648.
16. Yusuf S, Reddy S, Ôunpuu S and Anand S. Global burden of cardiovascular diseases part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. Circulation 2001; 104: 2855-2864.
17. Xi B, He D, Hu Y and Zhou D. Prevalence of metabolic syndrome and its influencing factors among the Chinese adults: the China Health and Nutrition Survey in 2009. Prev Med 2013; 57: 867-871.
18. Wallenius V, Wallenius K, Ahrén B, Rudling M, Carlsten H, Dickson SL, Ohlsson C and Jansson JO. Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 2002; 8: 75-79.
19. Sinaiko AR, Jacobs DR, Steinberger J, Moran A, Luepker R, Rocchini AP and Prineas RJ. Insulin resistance syndrome in childhood: associations of the euglycemic insulin clamp and fasting insulin with fatness and other risk factors. J Pediatr 2001; 139: 700-707.
20. Basu R, Singh RJ, Basu A, Chittilapilly EG, Johnson CM, Toffolo G, Cobelli C and Rizza RA. Splanchnic cortisol production occurs in humans evidence for conversion of cortisone to cortisol via the 11-β hydroxysteroid dehydrogenase (11β-HSD) type 1 pathway. Diabetes 2004; 53: 2051-2059.
21. Zhou X, Han D, Xu R, Li S, Wu H, Qu C, Wang F, Wang X and Zhao Y. A Model of Metabolic Syndrome and Related Diseases with Intestinal Endotoxemia in Rats Fed a High Fat and High Sucrose Diet. PLoS One 2014; 9: e115148.
22. Rao M, Guo D, Perianayagam MC, Tighiouart H, Jaber BL, Pereira BJ and Balakrishnan VS. Plasma interleukin-6 predicts cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2005; 45: 324-333.
23. Heresi GA, Aytekin M, Hammel JP, Wang S, Chatterjee S and Dweik RA. Plasma interleukin-6 adds prognostic information in pulmonary arterial hypertension. European Respiratory Journal 2014; 43: 912-914.
24. Bernberg E, Ulleryd MA, Johansson ME and Bergström GM. Social disruption stress increases IL-6 levels and accelerates atherosclerosis in ApoE-/-mice. Atherosclerosis 2012; 221: 359-365.
25. Blake G and Ridker P. Inflammatory bio‐markers and cardiovascular risk prediction. J Intern Med 2002; 252: 283-294.
26. Moller DE and Kaufman KD. Metabolic syndrome: a clinical and molecular perspective. Annu Rev Med 2005; 56: 45-62.
27. Moreira GC, Cipullo JP, Ciorlia LAS, Cesarino CB and Vilela-Martin JF. Prevalence of Metabolic Syndrome: Association with Risk Factors and Cardiovascular Complications in an Urban Population. PLoS One 2014; 9: e105056.
28. Gadonski G, LaMarca BBD, Sullivan E, Bennett W, Chandler D and Granger JP. Hypertension Produced by Reductions in Uterine Perfusion in the Pregnant Rat Role of Interleukin 6. Hypertension 2006; 48: 711-716.
29. Fernández-Real JM, Broch M, Vendrell Cristóbal Richart J and Ricart W. Interleukin-6 gene polymorphism and lipid abnormalities in healthy subjects. J Clin Endocrinol Metab 2000; 85: 1334-1339.
30. Salazar MR, Carbajal HA, Espeche WG, Dulbecco CA, Aizpurúa M, Marillet AG, Echeverría RF and Reaven GM. Relationships among insulin resistance, obesity, diagnosis of the metabolic syndrome and cardio-metabolic risk. Diab Vasc Dis Res 2011; 8: 109-116.
31. Dandona P, Aljada A and Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 2004; 25: 4-7.
32. Matsubara T, Mita A, Minami K, Hosooka T, Kitazawa S, Takahashi K, Tamori Y, Yokoi N, Watanabe M and Matsuo E. PGRN is a key adipokine mediating high fat diet-induced insulin resistance and obesity through IL-6 in adipose tissue. Cell Metab 2012; 15: 38-50.
33. Hu FB, Meigs JB, Li TY, Rifai N and Manson JE. Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes 2004; 53: 693-700.
34. Kim Y, Kim Y, Cho Y, Kim D, Ahn S, Lee J, Chanda D, Shong M, Lee C and Choi H. Metformin ameliorates IL-6-induced hepatic insulin resistance via induction of orphan nuclear receptor small heterodimer partner (SHP) in mouse models. Diabetologia 2012; 55: 1482-1494.
35. Holmes AG, Mesa JL, Neill BA, Chung J, Carey AL, Steinberg GR, Kemp BE, Southgate RJ, Lancaster GI and Bruce CR. Prolonged interleukin-6 administration enhances glucose tolerance and increases skeletal muscle PPARα and UCP2 expression in rats. J Endocrinol 2008; 198: 367-374.
36. Juge-Aubry CE, Henrichot E and Meier CA. Adipose tissue: a regulator of inflammation. Best Pract Res Clin Endocrinol Metab 2005; 19: 547-566.
37. Pini M, Castellanos KJ, Rhodes DH and Fantuzzi G. Obesity and IL-6 interact in modulating the response to endotoxemia in mice. Cytokine 2013; 61: 71-77.
38. Roytblat L, Rachinsky M, Fisher A, Greemberg L, Shapira Y, Douvdevani A and Gelman S. Raised Interleukin-6 Levels in Obese Patients. Obesity Res 2000; 8: 673-675.
39. Blüher M, Fasshauer M, Tönjes A, Kratzsch J, Schön M and Paschke R. Association of interleukin-6, C-reactive protein, interleukin-10 and adiponectin plasma concentrations with measures of obesity, insulin sensitivity and glucose metabolism. Exp Clin Endocrinol Diabetes 2005; 113: 534-537.
40. Cartier A, Lemieux I, Alméras N, Tremblay A, Bergeron J and Després JP. Visceral obesity and plasma glucose-insulin homeostasis: contributions of interleukin-6 and tumor necrosis factor-α in men. J Clin Endocrinol Metab 2008; 93: 1931-1938.
41. McGill HC Jr, McMahan CA, Herderick EE, Malcom GT, Tracy RE and Strong JP. Origin of atherosclerosis in childhood and adolescence. Am J Clin Nutr 2000; 72: 1307s-1315s.
42. Fernandez-Real J and Pickup J. Innate immunity, insulin resistance and type 2 diabetes. Diabetologia 2012; 55: 273-278.
43. Pedersen B. IL-6 signalling in exercise and disease. Biochem Soc Trans 2007; 35: 1295-1297.